Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Zacks
在Zacks上打开
Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

Abbott’s ABT Medical Devices segment delivered 8% sales growth in the third quarter of 2026, with Electrophysiology (“EP”) serving as a key contributor. Excluding left atrial appendage (LAA) products, EP sales grew at a mid-to-high-teens rate globally and more than 20% in the United States. Adoption of its Volt pulsed field ablation (PFA) catheter accelerated in September following its full U.S. market release in mid-August. International growth also picked up, supported by market share gains in Europe as adoption of Abbott’s new PFA catheters increased, along with growth across other product categories.

The company is also expanding the EP portfolio. In September, Abbott received FDA approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled, ahead of schedule. The device allows physicians to use PFA, radiofrequency (RF) energy or a combination of both during a procedure, giving them greater flexibility to tailor treatment to each patient. A broader U.S. launch is expected in the fourth quarter, supported by physicians’ familiarity with the TactiFlex platform. In August, Abbott received CE Mark for the Amulet 360 LAA Occluder, designed to reduce risk of stroke in patients with atrial fibrillation (AFib) not caused by a heart valve issue.

Abbott expects the fourth-quarter launch of Volt in Japan to help turn the market from a headwind into a tailwind. Japan has followed a similar adoption pattern to the United States, where demand for PFA technology has grown rapidly. The company also expects Volt to contribute for a full quarter in the U.S. market in the fourth quarter.

However, weakness in the LAA market is creating an increasing headwind for the EP business. U.S. orders slowed almost immediately following CE Mark approval for Amulet 360, as some accounts appear to be delaying purchases while awaiting the new device. Management expects this trend to continue through the fourth quarter, offsetting some of the growth acceleration in the ablation business.

Updates From ABT Peers

Thermo Fisher Scientific TMO reported third-quarter 2026 revenues of $12.14 billion, up 9% year over year. Profitability also improved, with adjusted operating margin expanding by 120 basis points (bps) to 24.5% and adjusted earnings by 15% to $6.68 per share. Thermo Fisher’s pharma and biotech end market delivered high single-digit growth, driven by the pharma services and clinical research businesses, and the research and safety market channel.

Insulet PODD reported revenues of $842 million, up nearly 20% year over year, with U.S. sales growing 15% and international revenues rising 33%. New customer starts were balanced between type 1 and type 2 diabetes patients globally, while type 2 patients accounted for more than 40% of new starts in the United States. Insulet’s adjusted gross margin rose 200 bps, adjusted operating margin grew 490 bps, and adjusted earnings per share surged 60% year over year.

ABT’s Price Performance, Valuation & Estimates

Over the past year, ABT shares have plunged 16.5% compared with the industry’s 20.7% decline. 

Zacks Investment Research
Image Source: Zacks Investment Research

In terms of valuation, Abbott is trading at a forward 12-month Price/Sales (P/S) of 3.54X, above its industry average of 2.30X.

Zacks Investment Research
Image Source: Zacks Investment Research

Here’s how consensus estimates for Abbott’s earnings currently stand.

Zacks Investment Research
Image Source: Zacks Investment Research

Abbott currently carries a Zacks Rank #3 (Hold).  You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

7 Best Stocks for the Next 30 Days

Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."

Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention. 

See them now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Abbott Laboratories (ABT): Free Stock Analysis Report
 
Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report
 
Insulet Corporation (PODD): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research